LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that three abstracts for CA-4948, a small molecule IRAK4
inhibitor, have been accepted for oral and poster presentation at
the 62nd American Society of Hematology Annual Meeting
and Exposition (ASH) which will be held virtually from December 5-8, 2020.
"We are pleased with the progress to date for our first-in-class
IRAK4 kinase inhibitor, CA-4948 and are on track to report data by
year-end for both our Phase 1 study in patients with non-Hodgkin's
lymphoma and our Phase 1 study in patients with acute myeloid
leukemia and myelodysplastic syndromes," said James Dentzer, President and Chief Executive
Officer of Curis. "In addition to the data published in the
abstracts this morning, we look forward to providing updated safety
and efficacy data at ASH from both studies."
Details of the presentations are as follows:
Oral Presentation:
- Title: Safety, Pharmacokinetics and Activity of CA-4948,
an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or
Refractory Hematologic Malignancies: Results from the Phase 1
Study
- Author: Grzegorz S. Nowakowski, MD, Mayo
Clinic
- Session Name: 623. Mantle Cell and Indolent B-Cell
Lymphoma - CAR-T and immunotherapy clinical studies
- Session Date & Time: Monday,
December 7, 2020, 1:30 pm –
3:00 pm ET
- Presentation Time: 2:15
pm
Poster Presentation
- Title: A Phase 1, Open Label Dose Escalation Trial
Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and
Clinical Activity of Orally Administered CA-4948 in Patients with
Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Author: Guillermo Garcia-Manero, MD, MD Anderson
Cancer Center
- Session Name: 616. Acute Myeloid Leukemia: Novel
Therapy, excluding Transplantation: Poster III
- Session Date & Time: Monday, December 7, 2020,
10:00 a.m. – 6:30 p.m. ET
Poster Presentation
- Title: A Multi-Center, Dose-Finding Study to Assess
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of
a novel IRAK4 inhibitor CA-4948 in combination with ibrutinib, in
Patients with Relapsed or Refractory Hematologic Malignancies
- Author: Grzegorz S. Nowakowski, MD, Mayo
Clinic
- Session Name: 623. Mantle Cell, Follicular, and
Other Indolent B-Cell Lymphoma —Clinical Studies: Poster III
- Session Date & Time: Monday, December 7, 2020,
10:00 a.m. – 6:30 p.m. ET
Additional meeting information can be found on the ASH website
at www.hematology.org/Annual-Meeting/. Each presentation will also
be available under "Events and Presentations" in the Investors
section of the Company's website at www.curis.com
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including, the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with non-Hodgkin
lymphoma and in a Phase 1 trial in patients with acute myeloid
leukemia and myelodysplastic syndromes. In addition, Curis is
engaged in a collaboration with ImmuNext for development of
CI-8993, a monoclonal anti-VISTA antibody, which is currently
undergoing testing in a Phase 1a/1b
trial in patients with solid tumors. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge®
for the treatment of advanced basal cell carcinoma. For more
information, visit Curis' website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-announces-three-abstracts-for-ca-4948-accepted-for-presentation-at-the-62nd-american-society-of-hematology-annual-meeting-and-exposition-301166526.html
SOURCE Curis, Inc.